BE2014C052I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2014C052I2 BE2014C052I2 BE2014C052C BE2014C052C BE2014C052I2 BE 2014C052 I2 BE2014C052 I2 BE 2014C052I2 BE 2014C052 C BE2014C052 C BE 2014C052C BE 2014C052 C BE2014C052 C BE 2014C052C BE 2014C052 I2 BE2014C052 I2 BE 2014C052I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Environmental Sciences (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33274301P | 2001-11-14 | 2001-11-14 | |
PCT/US2002/036213 WO2004039826A1 (en) | 2001-11-14 | 2002-10-26 | Anti-il-6 antibodies, compositions, methods and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2014C052I2 true BE2014C052I2 (fi) | 2022-02-01 |
Family
ID=34699762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2014C052C BE2014C052I2 (fi) | 2001-11-14 | 2014-09-04 |
Country Status (26)
Country | Link |
---|---|
US (7) | US7291721B2 (fi) |
EP (2) | EP1562968B1 (fi) |
JP (1) | JP2007528691A (fi) |
KR (1) | KR20100120246A (fi) |
CN (1) | CN100374457C (fi) |
AR (1) | AR037384A1 (fi) |
AU (1) | AU2002346369B2 (fi) |
BE (1) | BE2014C052I2 (fi) |
BR (1) | BRPI0214168B8 (fi) |
CA (1) | CA2467719C (fi) |
CY (3) | CY1114738T1 (fi) |
DK (2) | DK1562968T3 (fi) |
ES (2) | ES2624547T3 (fi) |
FR (1) | FR14C0064I2 (fi) |
HK (2) | HK1079213A1 (fi) |
IL (1) | IL161968A0 (fi) |
LU (1) | LU92543I2 (fi) |
MX (1) | MXPA04004671A (fi) |
MY (1) | MY142290A (fi) |
NL (1) | NL300687I2 (fi) |
NO (3) | NO334574B1 (fi) |
NZ (1) | NZ533223A (fi) |
PT (2) | PT1562968E (fi) |
RU (1) | RU2318829C2 (fi) |
TW (1) | TWI329019B (fi) |
WO (1) | WO2004039826A1 (fi) |
Families Citing this family (158)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060078533A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
AR048210A1 (es) * | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
DE602005020743D1 (de) * | 2004-02-11 | 2010-06-02 | Warner Lambert Co | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern |
ES2523147T3 (es) | 2004-02-26 | 2014-11-21 | Baylor Research Institute | Composiciones y métodos para el tratamiento sistémico de la artritis |
CA2580965C (en) | 2004-09-22 | 2014-04-08 | Receptor Biologix, Inc. | Monoclonal antibodies to progastrin |
US20090041783A1 (en) | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
JP5224707B2 (ja) * | 2005-04-28 | 2013-07-03 | 持田製薬株式会社 | 抗血小板膜糖蛋白質viモノクローナル抗体 |
JO3058B1 (ar) * | 2005-04-29 | 2017-03-15 | Applied Molecular Evolution Inc | الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها |
US8470316B2 (en) | 2005-10-14 | 2013-06-25 | Chugai Seiyaku Kabushiki Kaisha | Agents for suppressing damage to transplanted islets after islet transplantation |
CN101330930B (zh) * | 2005-10-21 | 2011-11-23 | 中外制药株式会社 | 心脏病治疗剂 |
AR057582A1 (es) * | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
KR20080084818A (ko) * | 2005-11-25 | 2008-09-19 | 각고호우징 게이오기주크 | 전립선암 치료제 |
AR057227A1 (es) * | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
PL1960430T3 (pl) * | 2005-12-09 | 2015-03-31 | Ucb Pharma Sa | Cząsteczki przeciwciał wykazujące swoistość dla ludzkiej il-6 |
EA200870130A1 (ru) * | 2005-12-30 | 2009-02-27 | Мерк Патент Гмбх | Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6 |
WO2007100937A2 (en) * | 2006-01-19 | 2007-09-07 | The Regents Of The University Of Michigan | System and method for spectroscopic photoacoustic tomography |
AU2007208678B2 (en) | 2006-01-27 | 2013-01-10 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agents for diseases involving choroidal neovascularization |
JP5754875B2 (ja) | 2006-04-07 | 2015-07-29 | 国立大学法人大阪大学 | 筋再生促進剤 |
MX2008014692A (es) * | 2006-05-19 | 2009-08-18 | Alder Biopharmaceuticals Inc | Metodo de cultivo para obtener una poblacion clonal de celulas b especificas de antigeno. |
MX2009001110A (es) * | 2006-08-03 | 2009-05-11 | Vaccinex Inc | Anticuerpos monoclonales anti-il-6 y usos de los mismos. |
US20080081041A1 (en) * | 2006-09-29 | 2008-04-03 | Jeffrey Nemeth | Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer |
US8414897B1 (en) * | 2006-10-02 | 2013-04-09 | The Uab Research Foundation | Pathway for Th-17 cell development and methods utilizing same |
AU2012200284B2 (en) * | 2006-10-06 | 2014-03-06 | Amgen Inc. | Stable Antibody Formulations |
US20080112953A1 (en) * | 2006-10-06 | 2008-05-15 | Amgen Inc. | Stable formulations |
PE20080857A1 (es) | 2006-10-20 | 2008-08-19 | Amgen Inc | Formulaciones a base de polipeptidos estables |
WO2008067438A2 (en) * | 2006-11-29 | 2008-06-05 | The Regents Of University Of Michigan | System and method for photoacoustic guided diffuse optical imaging |
TW200831528A (en) | 2006-11-30 | 2008-08-01 | Astrazeneca Ab | Compounds |
US8136651B2 (en) * | 2007-12-14 | 2012-03-20 | The Procter & Gamble Company | Method and apparatus for orienting articles |
US7854932B2 (en) | 2006-12-19 | 2010-12-21 | The Board Of Regents Of The University Of Texas System | Immunogenic compositions comprising progastrin and uses thereof |
JP2010095445A (ja) * | 2006-12-27 | 2010-04-30 | Tokyo Medical & Dental Univ | Il−6アンタゴニストを有効成分とする炎症性筋疾患治療剤 |
US9725514B2 (en) | 2007-01-23 | 2017-08-08 | Shinshu University | Chronic rejection inhibitor |
WO2008135419A2 (en) * | 2007-05-04 | 2008-11-13 | Charité Universitätsmedizin Berlin | Anti-il-6-agents for improving primary functioning of allogenic grafts |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
TWI561530B (en) | 2007-05-21 | 2016-12-11 | Alderbio Holdings Llc | Antibodies to il-6 and use thereof |
US8252286B2 (en) * | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
WO2008144753A2 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Antibodies to tnf alpha and use thereof |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
TWI609965B (zh) * | 2007-05-21 | 2018-01-01 | 艾爾德生物控股有限責任公司 | 新穎兔抗體人化方法以及經人化之兔抗體 |
EP3293269A1 (en) | 2007-08-03 | 2018-03-14 | MUSC Foundation For Research Development | Human monoclonal antibodies and methods for producing the same |
GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
US20100203009A1 (en) * | 2007-10-02 | 2010-08-12 | The Uab Research Foundation | Pathway for Th-17 Cell Development and Methods Utilizing Same |
KR101601986B1 (ko) | 2007-10-02 | 2016-03-17 | 추가이 세이야쿠 가부시키가이샤 | 인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제 |
CA2703705A1 (en) * | 2007-11-05 | 2009-05-14 | Medimmune, Llc | Methods of treating scleroderma |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
CN103251948A (zh) | 2008-04-11 | 2013-08-21 | 中外制药株式会社 | 与多个分子的抗原反复结合的抗原结合分子 |
AU2009241589B2 (en) | 2008-04-29 | 2013-10-10 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
US8034344B2 (en) | 2008-05-13 | 2011-10-11 | Novimmune S.A. | Anti-IL-6/IL-6R antibodies and methods of use thereof |
EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
MX2010013236A (es) | 2008-06-03 | 2011-02-24 | Abbott Lab | Inmunoglobulinas de dominio variable doble y usos de las mismas. |
US10717781B2 (en) | 2008-06-05 | 2020-07-21 | National Cancer Center | Neuroinvasion inhibitor |
US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
KR20110043643A (ko) * | 2008-07-02 | 2011-04-27 | 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 | 인터루킨 6 면역치료제 |
MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
CN104974251A (zh) * | 2008-10-20 | 2015-10-14 | Abbvie公司 | 在抗体纯化过程中的病毒灭活 |
JP2012506384A (ja) * | 2008-10-20 | 2012-03-15 | アボット・ラボラトリーズ | Il−12に結合する抗体およびそれを精製する方法 |
CN102245207B (zh) * | 2008-11-13 | 2015-11-25 | 费塔制药股份有限公司 | 人源化抗il-6抗体 |
US8337847B2 (en) * | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US8323649B2 (en) * | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
AU2016250477B2 (en) * | 2008-11-25 | 2018-07-05 | Vitaeris Inc. | Antagonists of IL-6 to raise albumin and/or lower CRP |
WO2010065077A2 (en) * | 2008-11-25 | 2010-06-10 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat thrombosis |
AU2010208125B2 (en) * | 2009-01-29 | 2015-02-12 | Medimmune, Llc | Human anti-IL-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
KR101468271B1 (ko) * | 2009-03-19 | 2014-12-03 | 추가이 세이야쿠 가부시키가이샤 | 개량된 항체분자를 함유하는 의약 제제 |
SG174862A1 (en) * | 2009-04-10 | 2011-11-28 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder |
PE20121530A1 (es) * | 2009-09-01 | 2012-12-22 | Abbvie Inc | Inmunoglobulinas con dominio variable dual |
JP2013503919A (ja) * | 2009-09-08 | 2013-02-04 | ヤンセン バイオテツク,インコーポレーテツド | 癌患者においてヘプシジンを減少させるための抗il−6抗体の使用 |
US8716450B2 (en) | 2009-10-15 | 2014-05-06 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
US20120269814A1 (en) * | 2009-11-10 | 2012-10-25 | Amgen Inc. | Anti-c mpl antibodies |
WO2011066374A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
EP2516467A2 (en) | 2009-12-23 | 2012-10-31 | Emergent Product Development Seattle, LLC | Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
DE102010007562A1 (de) * | 2010-02-10 | 2011-08-11 | sterna biologicals GmbH & Co KG, 35043 | Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide |
RS61082B1 (sr) | 2010-02-26 | 2020-12-31 | Novo Nordisk As | Stabilno antitelo koje sadrži kompozicije |
US20120323158A1 (en) * | 2010-03-10 | 2012-12-20 | Paul Tebbey | Extracorporeal immunoadsorption treatment |
SI2578231T1 (sl) | 2010-05-28 | 2023-01-31 | Chugai Seiyaku Kabushiki Kaisha | Okrepljen protitumorski T celični odzivnik |
RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
EP2596023A4 (en) * | 2010-07-20 | 2014-03-05 | Beth Israel Hospital | COMPOSITIONS AND METHODS COMPRISING ANTAGONISTS OF IL-6 AND IL-21 |
RU2013109275A (ru) | 2010-08-03 | 2014-09-10 | Эббви Инк. | Иммуноглобулины с двумя вариабельными доменами и их применение |
WO2012021407A2 (en) * | 2010-08-13 | 2012-02-16 | Morehouse School Of Medicine | Biomarkers for stroke |
KR20130139884A (ko) | 2010-08-26 | 2013-12-23 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
ES2847891T3 (es) | 2010-11-23 | 2021-08-04 | Vitaeris Inc | Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral |
CN107973851A (zh) | 2010-11-30 | 2018-05-01 | 中外制药株式会社 | 与多分子的抗原重复结合的抗原结合分子 |
US8696616B2 (en) | 2010-12-29 | 2014-04-15 | Ethicon Endo-Surgery, Inc. | Obesity therapy and heart rate variability |
CN102161998B (zh) * | 2011-01-14 | 2013-01-09 | 中国人民解放军军事医学科学院附属医院 | 基于b7-1-pe40kdel外毒素融合基因的dna疫苗及其用途 |
US20120189621A1 (en) | 2011-01-21 | 2012-07-26 | Yann Dean | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists |
US20140093496A1 (en) | 2011-02-25 | 2014-04-03 | Chugai Seiyaku Kabushiki Kaisha | Fc-gamma-RIIb-SPECIFIC Fc ANTIBODY |
TW201817745A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
KR102239138B1 (ko) * | 2011-09-30 | 2021-04-12 | 추가이 세이야쿠 가부시키가이샤 | 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자 |
JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US20150056182A1 (en) | 2011-11-30 | 2015-02-26 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
TW201333035A (zh) | 2011-12-30 | 2013-08-16 | Abbvie Inc | 針對il-13及/或il-17之雙特異性結合蛋白 |
WO2013175276A1 (en) * | 2012-05-23 | 2013-11-28 | Argen-X B.V | Il-6 binding molecules |
ES2662020T3 (es) | 2012-10-22 | 2018-04-05 | Fountain Biopharma Inc. | Anticuerpos contra la interleucina-6 y sus usos |
RU2017137740A (ru) | 2012-11-01 | 2019-02-11 | Эббви Инк. | Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения |
US9168000B2 (en) | 2013-03-13 | 2015-10-27 | Ethicon Endo-Surgery, Inc. | Meal detection devices and methods |
BR112015023797A2 (pt) | 2013-03-15 | 2017-10-24 | Abbvie Inc | proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17 |
WO2015120392A1 (en) | 2014-02-10 | 2015-08-13 | Patara Pharma, LLC | Mast cell stabilizers for lung disease treatment |
DK3104853T3 (da) | 2014-02-10 | 2019-12-09 | Respivant Sciences Gmbh | Behandling med mastcellestabilisatorer til systemiske forstyrrelser |
RU2550262C1 (ru) * | 2014-02-28 | 2015-05-10 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело |
CN105037548B (zh) * | 2014-04-21 | 2018-08-03 | 上海市免疫学研究所 | 抗人白介素-6受体β链单克隆抗体、其制备方法和用途 |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
PL3233921T3 (pl) | 2014-12-19 | 2022-01-10 | Chugai Seiyaku Kabushiki Kaisha | Przeciwciała anty-c5 i sposoby ich stosowania |
MA41294A (fr) | 2014-12-19 | 2017-11-08 | Chugai Pharmaceutical Co Ltd | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation |
WO2016125495A1 (en) | 2015-02-05 | 2016-08-11 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
US11174317B2 (en) | 2015-06-04 | 2021-11-16 | National Center Of Neurology And Psychiatry | Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
CA2991637C (en) | 2015-07-31 | 2022-07-05 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
WO2017027402A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
WO2017027387A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
JP2019519470A (ja) * | 2016-04-07 | 2019-07-11 | ヤンセン バイオテツク,インコーポレーテツド | Il−6受容体へのil−6の結合を遮断する薬剤を用いたうつ病の治療 |
AU2017261292B2 (en) * | 2016-05-05 | 2024-06-06 | The Trustees Of The University Of Pennsylvania | DNA monoclonal antibodies targeting IL-6 and CD126 |
RU2766112C2 (ru) | 2016-08-05 | 2022-02-08 | Чугаи Сейяку Кабусики Кайся | Композиция для профилактики или лечения связанных с il-8 заболеваний |
AU2017321495A1 (en) | 2016-08-31 | 2019-03-21 | Respivant Sciences Gmbh | Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis |
CN109803724A (zh) | 2016-10-07 | 2019-05-24 | 瑞思皮万特科学有限责任公司 | 用于治疗肺纤维化的色甘酸组合物 |
JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
KR20200012823A (ko) | 2017-02-01 | 2020-02-05 | 예일 유니버시티 | 이뇨제 내성의 치료 |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
CA3066756A1 (en) | 2017-06-15 | 2018-12-20 | Cancer Advances Inc. | Compositions and methods for inducing humoral and cellular immunities against tumors and cancer |
CN111093710A (zh) * | 2017-07-13 | 2020-05-01 | 希望之城 | 硫代磷酸酯缀合的肽及其使用方法 |
US20210128615A1 (en) | 2017-10-18 | 2021-05-06 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Methods and compounds for improved immune cell therapy |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
CN109867723B (zh) * | 2017-12-05 | 2022-06-17 | 南京金斯瑞生物科技有限公司 | 抗人il6单克隆抗体及其制备方法和用途 |
KR20200116089A (ko) | 2018-01-05 | 2020-10-08 | 코비디아 테라퓨틱스, 인크. | 면역억제 없이 il-6 매개 염증을 치료하기 위한 방법 |
JP7429192B2 (ja) * | 2018-04-06 | 2024-02-07 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | Hhla2受容体としてのkir3dl3、抗hhla2抗体、およびその使用 |
CN109517064B (zh) * | 2018-10-10 | 2020-05-08 | 北京汇智和源生物技术有限公司 | 白介素-6的人源化单克隆抗体、其编码基因及应用 |
AU2019385497A1 (en) | 2018-11-20 | 2021-06-17 | Cornell University | Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer |
WO2020160465A1 (en) | 2019-01-31 | 2020-08-06 | Sanofi Biotechnology | Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis |
WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
JP2022531331A (ja) | 2019-05-01 | 2022-07-06 | ノヴォ ノルディスク アー/エス | 抗il-6抗体製剤 |
US20200405883A1 (en) | 2019-06-20 | 2020-12-31 | Baxalta Incorporated | Method of treatment with viral-based gene therapy |
DE112020002988T5 (de) * | 2019-08-05 | 2022-05-19 | Agency For Science, Technology And Research | Kombinationstherapie zur erzielung einer erhöhten antimikrobiellen aktivität |
EP4041312A4 (en) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | METHOD FOR TREATING AN EYE DISORDER |
WO2022157493A1 (en) | 2021-01-21 | 2022-07-28 | Eusa Pharma (Uk) Limited | Method for treating il-6 associated histiocytic and lymphoproliferative disorders |
WO2022162357A1 (en) | 2021-01-28 | 2022-08-04 | Eusa Pharma (Uk) Limited | Methods for treating igg4-related disease with anti-il-6 therapy |
WO2022162354A1 (en) | 2021-01-28 | 2022-08-04 | Eusa Pharma (Uk) Limited | Methods for treating rare disorders with anti-il-6 therapy |
WO2022162358A1 (en) | 2021-01-28 | 2022-08-04 | Eusa Pharma (Uk) Limited | Methods for treating rare disorders with anti-il-6 therapy |
WO2022162351A1 (en) | 2021-01-28 | 2022-08-04 | Eusa Pharma (Uk) Limited | Methods for treating rare disorders with anti-il-6 therapy |
WO2022162352A1 (en) | 2021-01-28 | 2022-08-04 | Eusa Pharma (Uk) Limited | Methods for treating rare disorders with anti-il-6 therapy |
CN113057142B (zh) * | 2021-03-30 | 2022-12-09 | 四川大学华西医院 | 一种视网膜内和/或视网膜下纤维化动物模型的构建方法 |
CN114478672B (zh) * | 2022-01-27 | 2024-06-14 | 浙江仙居君业药业有限公司 | 一种he3286的合成方法 |
CN117247451B (zh) * | 2023-11-17 | 2024-02-09 | 中国人民解放军军事科学院军事医学研究院 | 一种针对人白介素6蛋白的单域抗体及其应用 |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4309989A (en) | 1976-02-09 | 1982-01-12 | The Curators Of The University Of Missouri | Topical application of medication by ultrasound with coupling agent |
FR2374910A1 (fr) | 1976-10-23 | 1978-07-21 | Choay Sa | Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US5326859A (en) * | 1979-10-30 | 1994-07-05 | Juridical Foundation, Japanese Foundation For Cancer Research | DNA and recombinant plasmid |
IL58765A (en) * | 1979-11-21 | 1986-09-30 | Yeda Res & Dev | Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta |
US5554513A (en) * | 1979-11-21 | 1996-09-10 | Yeda Research & Development Co. Ltd. | Production of recombinant human interferon-beta2 |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
US5149636A (en) | 1982-03-15 | 1992-09-22 | Trustees Of Columbia University In The City Of New York | Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) * | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
EP1186660A3 (fr) | 1985-03-30 | 2002-03-20 | KAUFFMAN, Stuart A. | Procédé d'obtension d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombination d'ADN |
SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
US4766067A (en) | 1985-05-31 | 1988-08-23 | President And Fellows Of Harvard College | Gene amplification |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
SE453566B (sv) | 1986-03-07 | 1988-02-15 | Draco Ab | Anordning vid pulverinhalatorer |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
AU610083B2 (en) | 1986-08-18 | 1991-05-16 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
US4795699A (en) | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
US4921794A (en) | 1987-01-14 | 1990-05-01 | President And Fellows Of Harvard College | T7 DNA polymerase |
EP0832981A1 (en) | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA sequences to target proteins to the mammary gland for efficient secretion |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
IL88375A (en) | 1988-11-14 | 1995-07-31 | Yeda Res & Dev | Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method |
US6010902A (en) | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
US4956288A (en) | 1988-04-22 | 1990-09-11 | Biogen, Inc. | Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA |
US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
US5091310A (en) | 1988-09-23 | 1992-02-25 | Cetus Corporation | Structure-independent dna amplification by the polymerase chain reaction |
US5066584A (en) | 1988-09-23 | 1991-11-19 | Cetus Corporation | Methods for generating single stranded dna by the polymerase chain reaction |
US5142033A (en) | 1988-09-23 | 1992-08-25 | Hoffmann-La Roche Inc. | Structure-independent DNA amplification by the polymerase chain reaction |
US6682896B1 (en) * | 1988-10-14 | 2004-01-27 | Schering Aktiengesellschaft | Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US4994370A (en) | 1989-01-03 | 1991-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | DNA amplification technique |
US5266491A (en) | 1989-03-14 | 1993-11-30 | Mochida Pharmaceutical Co., Ltd. | DNA fragment and expression plasmid containing the DNA fragment |
DE3909708A1 (de) | 1989-03-23 | 1990-09-27 | Boehringer Mannheim Gmbh | Verfahren zur herstellung bispezifischer antikoerper |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
WO1990014443A1 (en) | 1989-05-16 | 1990-11-29 | Huse William D | Co-expression of heteromeric receptors |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
JPH05503098A (ja) | 1989-12-15 | 1993-05-27 | カイロン コーポレイション | セプシスの処理のためのサイトカイン抗体 |
US5580575A (en) | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5358673A (en) * | 1990-02-15 | 1994-10-25 | 3D Systems, Inc. | Applicator device and method for dispensing a liquid medium in a laser modeling machine |
US5942220A (en) * | 1990-03-16 | 1999-08-24 | Chiron Corporation | Inhibitor of cytokine activity and applications thereof |
TW212184B (fi) | 1990-04-02 | 1993-09-01 | Takeda Pharm Industry Co Ltd | |
ATE204902T1 (de) | 1990-06-29 | 2001-09-15 | Large Scale Biology Corp | Melaninproduktion durch transformierte mikroorganismen |
US5580734A (en) | 1990-07-13 | 1996-12-03 | Transkaryotic Therapies, Inc. | Method of producing a physical map contigous DNA sequences |
ATE160379T1 (de) | 1990-10-29 | 1997-12-15 | Chiron Corp | Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen |
US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
US5404871A (en) | 1991-03-05 | 1995-04-11 | Aradigm | Delivery of aerosol medications for inspiration |
GEP20033082B (en) | 1991-03-15 | 2003-10-27 | Amgen Inc | Pegylation of Polypeptides |
DE4118120A1 (de) | 1991-06-03 | 1992-12-10 | Behringwerke Ag | Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung |
US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
AU662919B2 (en) | 1991-07-02 | 1995-09-21 | Inhale, Inc. | Method and device for delivering aerosolized medicaments |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
ATE249840T1 (de) | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
DE4207475A1 (de) | 1992-03-10 | 1993-09-16 | Goldwell Ag | Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung |
EP0583020B1 (en) * | 1992-05-20 | 1998-08-12 | Eastman Kodak Company | Photographic material with improved granularity |
WO1994006498A1 (en) | 1992-09-23 | 1994-03-31 | Fisons Plc | Inhalation device |
AU5322494A (en) | 1992-10-02 | 1994-04-26 | Trustees Of Dartmouth College | Bispecific reagents for redirected targeting of low density lipoprotein |
DK0665759T3 (da) | 1992-10-19 | 1999-08-23 | Dura Pharma Inc | Tørpulverinhalator |
JPH09505721A (ja) * | 1992-10-20 | 1997-06-10 | シータス オンコロジー コーポレイション | インターロイキン6レセプターアンタゴニスト |
US5643252A (en) | 1992-10-28 | 1997-07-01 | Venisect, Inc. | Laser perforator |
US5849695A (en) | 1993-01-13 | 1998-12-15 | The Regents Of The University Of California | Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals |
ATE172933T1 (de) | 1993-01-19 | 1998-11-15 | Glaxo Group Ltd | Aerosol-spender und verfahren zu seiner herstellung |
CN1119876A (zh) | 1993-02-12 | 1996-04-03 | 莱兰斯坦福初级大学评议会 | 被调节的靶向基因转录及其他生物学过程 |
JP3525221B2 (ja) * | 1993-02-17 | 2004-05-10 | 味の素株式会社 | 免疫抑制剤 |
US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
TW458985B (en) * | 1993-05-31 | 2001-10-11 | Chugai Pharmaceutical Co Ltd | Reconstructed human antibody against human interleukin-6 |
US5891998A (en) * | 1993-06-23 | 1999-04-06 | Istituto Di Ricerche Di Biologica Molecolare P. Angeletti S.P.A. | Interleukin-6 receptor agonists |
US5888510A (en) * | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
FR2707882B1 (fr) * | 1993-07-23 | 1997-08-01 | Immunotech Sa | Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant. |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
DE4337197C1 (de) | 1993-10-30 | 1994-08-25 | Biotest Pharma Gmbh | Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
ES2178669T3 (es) | 1994-03-07 | 2003-01-01 | Medarex Inc | Moleculas biespecificas que tienen utilidad clinica. |
US5641657A (en) * | 1994-05-19 | 1997-06-24 | Human Genome Sciences, Inc. | DNA encoding an interleukin-6 splice variant |
US8017121B2 (en) * | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
IT1274782B (it) * | 1994-12-14 | 1997-07-24 | Angeletti P Ist Richerche Bio | Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130 |
JP4079461B2 (ja) | 1994-12-29 | 2008-04-23 | 中外製薬株式会社 | Il−6アンタゴニストを含んでなる抗腫瘍剤の作用増強剤 |
ATE330629T1 (de) * | 1995-02-13 | 2006-07-15 | Chugai Pharmaceutical Co Ltd | Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6037453A (en) | 1995-03-15 | 2000-03-14 | Genentech, Inc. | Immunoglobulin variants |
IT1276555B1 (it) * | 1995-04-28 | 1997-11-03 | Angeletti P Ist Richerche Bio | Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
GB9526100D0 (en) | 1995-12-20 | 1996-02-21 | Intersurgical Ltd | Nebulizer |
ES2167987T3 (es) | 1996-01-03 | 2002-05-16 | Glaxo Group Ltd | Dispositivo inhalador. |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US5854398A (en) * | 1996-07-25 | 1998-12-29 | The Trustees Of Columbia University In The City Of New York | Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof |
DK0826695T3 (da) | 1996-09-03 | 2002-04-15 | Gsf Forschungszentrum Umwelt | Tilintetgørelse af kontaminerende tumorceller i stamcelletransplantater med bispecifikke antistoffer |
US5879681A (en) | 1997-02-07 | 1999-03-09 | Emisphere Technolgies Inc. | Compounds and compositions for delivering active agents |
US5921447A (en) | 1997-02-13 | 1999-07-13 | Glaxo Wellcome Inc. | Flow-through metered aerosol dispensing apparatus and method of use thereof |
JPH10302563A (ja) * | 1997-04-22 | 1998-11-13 | Yazaki Corp | グロメット |
IL120943A (en) | 1997-05-29 | 2004-03-28 | Univ Ben Gurion | A system for administering drugs through the skin |
US6011288A (en) * | 1997-12-22 | 2000-01-04 | Taiwan Semiconductor Manufacturing Company, Ltd. | Flash memory cell with vertical channels, and source/drain bus lines |
US7098309B2 (en) * | 1998-12-23 | 2006-08-29 | Merck & Co., Inc. | Recombinant hepatitis B surface antigen |
US20020010320A1 (en) * | 1999-04-05 | 2002-01-24 | James W. Fett | Chemeric and humanized antibodies to angiogenin |
KR20110032012A (ko) | 2000-02-10 | 2011-03-29 | 아보트 러보러터리즈 | 사람 인터류킨-18에 결합하는 항체 및 이를 제조하고 사용하는 방법 |
JP5470817B2 (ja) | 2008-03-10 | 2014-04-16 | 日産自動車株式会社 | 電池用電極およびこれを用いた電池、並びにその製造方法 |
TWI503850B (zh) | 2013-03-22 | 2015-10-11 | Polytronics Technology Corp | 過電流保護元件 |
TWI510996B (zh) | 2013-10-03 | 2015-12-01 | Acer Inc | 控制觸控面板的方法以及使用該方法的可攜式電腦 |
US9816280B1 (en) | 2016-11-02 | 2017-11-14 | Matthew Reitnauer | Portable floor |
-
2002
- 2002-10-26 DK DK02784436.4T patent/DK1562968T3/da active
- 2002-10-26 EP EP02784436.4A patent/EP1562968B1/en not_active Expired - Lifetime
- 2002-10-26 JP JP2004548246A patent/JP2007528691A/ja not_active Withdrawn
- 2002-10-26 EP EP10179049.1A patent/EP2308888B1/en not_active Expired - Lifetime
- 2002-10-26 ES ES10179049.1T patent/ES2624547T3/es not_active Expired - Lifetime
- 2002-10-26 AU AU2002346369A patent/AU2002346369B2/en active Active
- 2002-10-26 KR KR1020107024321A patent/KR20100120246A/ko not_active Application Discontinuation
- 2002-10-26 ES ES02784436T patent/ES2436206T3/es not_active Expired - Lifetime
- 2002-10-26 NZ NZ533223A patent/NZ533223A/en not_active IP Right Cessation
- 2002-10-26 CA CA2467719A patent/CA2467719C/en not_active Expired - Lifetime
- 2002-10-26 PT PT27844364T patent/PT1562968E/pt unknown
- 2002-10-26 BR BRPI0214168A patent/BRPI0214168B8/pt active IP Right Grant
- 2002-10-26 WO PCT/US2002/036213 patent/WO2004039826A1/en active Application Filing
- 2002-10-26 DK DK10179049.1T patent/DK2308888T3/en active
- 2002-10-26 IL IL16196802A patent/IL161968A0/xx active Protection Beyond IP Right Term
- 2002-10-26 US US10/280,716 patent/US7291721B2/en active Active
- 2002-10-26 RU RU2004114882/13A patent/RU2318829C2/ru active
- 2002-10-26 MX MXPA04004671A patent/MXPA04004671A/es active IP Right Grant
- 2002-10-26 CN CNB028298039A patent/CN100374457C/zh not_active Expired - Lifetime
- 2002-10-26 PT PT101790491T patent/PT2308888T/pt unknown
- 2002-11-13 TW TW091133208A patent/TWI329019B/zh active
- 2002-11-13 MY MYPI20024224A patent/MY142290A/en unknown
- 2002-11-14 AR ARP020104379A patent/AR037384A1/es active IP Right Grant
-
2004
- 2004-06-10 NO NO20042418A patent/NO334574B1/no not_active IP Right Cessation
-
2005
- 2005-12-08 HK HK05111243.7A patent/HK1079213A1/xx not_active IP Right Cessation
-
2006
- 2006-03-22 HK HK06103634A patent/HK1083509A1/xx not_active IP Right Cessation
-
2007
- 2007-08-01 US US11/832,323 patent/US7612182B2/en not_active Expired - Lifetime
- 2007-10-30 US US11/927,925 patent/US7833786B2/en not_active Expired - Lifetime
-
2009
- 2009-07-23 US US12/507,962 patent/US7955597B2/en not_active Expired - Fee Related
-
2011
- 2011-05-11 US US13/105,152 patent/US20110218329A1/en not_active Abandoned
- 2011-12-21 US US13/332,973 patent/US20120096569A1/en not_active Abandoned
-
2013
- 2013-07-25 NO NO20131043A patent/NO20131043L/no not_active Application Discontinuation
- 2013-09-19 CY CY20131100821T patent/CY1114738T1/el unknown
-
2014
- 2014-01-29 US US14/167,384 patent/US20140141013A1/en not_active Abandoned
- 2014-09-04 BE BE2014C052C patent/BE2014C052I2/nl unknown
- 2014-09-05 NL NL300687C patent/NL300687I2/nl unknown
- 2014-09-05 FR FR14C0064C patent/FR14C0064I2/fr active Active
- 2014-09-05 CY CY2014038C patent/CY2014038I1/el unknown
- 2014-09-05 LU LU92543C patent/LU92543I2/fr unknown
- 2014-09-24 NO NO2014025C patent/NO2014025I1/no unknown
-
2017
- 2017-05-12 CY CY20171100514T patent/CY1118955T1/el unknown